Multiple Companies

 
News Articles for Multiple Companies top ^
Biogen Idec (NASDAQ: BIIB) will present more than 90 company-sponsored platform and poster presentations on data supporting its marketed and investigational therapies for multiple sclerosis (MS), as well as the company’s programs to address unmet needs in patient management, at the sixth Triennial Joint Meeting of ACTRIMS and ECTRIMS in Boston, September 10 – 13, 2014.
Sign-up for Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that five-year results from the ENDORSE Phase 3 extension study show TECFIDERA ® (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis (RRMS). These data will be presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS). Across all patients in the ENDORSE study who received TECFIDERA, including some patients who were treated for up to seven and a half years, the safety profile remained consistent with no new or worsening safety signals.
Sign-up for New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY TM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe.
Sign-up for PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis investment picks
Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDY TM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). PLEGRIDY , the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe.
Sign-up for Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis investment picks
Today, INTERXION HOLDING NV (NYSE: INXN), a leading European provider of cloud and carrier-neutral colocation data centre services, launched its new service that enables private connections to multiple cloud service providers (CSPs). Cloud Connect will provide enterprises, service providers (SPs), system integrators (SIs) and carriers, private, secure and high performance connections to multiple clouds from within Interxion data centres, making it easier for them to shift business critical workloads and real time data to the cloud.
Sign-up for Interxion Launches Cloud Connect, Enabling Private Access to Multiple Clouds investment picks
2014/9/8
Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during the 30 th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) being held in Boston Sept.
Sign-up for Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at ECTRIMS investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). The randomized, double-blind study will evaluate the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers.
Sign-up for Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis investment picks
2014/7/31
-- Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition --
Sign-up for Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting investment picks
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in people with relapsing forms of multiple sclerosis (RMS) beyond the first year of the study.
Sign-up for PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients investment picks
First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study Trial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity Multiple Biomarkers to be Assessed DUBLIN, Ireland, July 31, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA) , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today that the first patient with Parkinson's disease has been successfully dosed in a Phase 1 multiple ascending dose clinical trial of PRX002, a potential disease-modifying treatment for Parkinson's disease.
Sign-up for Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease investment picks
2014/7/30
Article in "Neurosurgery" describes how RapidArc Radiosurgery treatments can be specially optimized to treat multiple brain metastases at the same time PALO ALTO, Calif.
Sign-up for Study Shows that RapidArc® Radiosurgery Substantially More Efficient and Comparable in Quality to Gamma Knife® in the Treatment of Multiple Brain Metastases investment picks
Results from a large-scale retrospective claims database study assessing real-world use of AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg will be presented by Acorda Therapeutics, Inc. (Nasdaq: ACOR ) and HealthCore Inc. at the 2014 Joint ACTRIMS-ECTRIMS Meeting.
Sign-up for Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on Multiple Sclerosis Therapy AMPYRA investment picks
Represents Second Subcontract Awarded to xG under this Multiple-Award Contract SARASOTA, Fla.
Sign-up for xG Technology Awarded Subcontract by CACI on $497 Million Multiple-Award Contract to Provide Communications and Networking Services to U.S. Army investment picks
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening Results to Form Basis of Regulatory Filings Beginning in 1H 2015 THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint investment picks
2014/8/14
SMART kapp wins Best New Product at InfoComm 2014 Audio-visual industry influencer rAVe also names SMART kapp as Best New Presentation Product SMART kapp named in multiple "Best of InfoComm" coverage CALGARY , Aug.
Sign-up for SMART kapp Earns Multiple Honors Following InfoComm Debut investment picks
Verint ® Systems Inc. (NASDAQ: VRNT) today announced that its Verint Mobile Workforce Optimization (WFO) solution is now available on multiple mobile platforms, including Google Android and Apple iOS.
Sign-up for Verint Workforce Optimization Solution Now Available on Multiple Mobile Platforms investment picks
Celgene Corporation (NASDAQ:CELG) today announced that data from FIRST (MM-020/IFM 07-01)—an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant—have been published in the Sept.
Sign-up for Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine investment picks
Biogen Idec (NASDAQ:BIIB) announced today a new program with Yahoo Health to raise awareness of innovative efforts to help people with multiple sclerosis (MS) across the country.
Sign-up for Biogen Idec and Yahoo Health Spotlight Visionaries Whose Work Benefits People with Multiple Sclerosis (MS) investment picks
NEW YORK (MarketWatch) -- Amgen Inc. shares (AMGN) climbed 3.5% in premarket trade Monday, after the company said a late-stage trial of a treatment for patients with relapsed multiple myeloma had positive results.
Sign-up for Amgen reports positive trial of multiple myeloma treatment investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Multiple Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Multinational Companies  |  Next: Multiple Managers